Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL). Men with low and intermediate-risk prostate cancer were randomly assign...
Gespeichert in:
| Veröffentlicht in: | Radiotherapy and oncology 2018-05, Vol.127 (2), p.206-212 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 212 |
|---|---|
| container_issue | 2 |
| container_start_page | 206 |
| container_title | Radiotherapy and oncology |
| container_volume | 127 |
| creator | Quon, Harvey C. Ong, Aldrich Cheung, Patrick Chu, William Chung, Hans T. Vesprini, Danny Chowdhury, Amit Panjwani, Dilip Pang, Geordi Korol, Renee Davidson, Melanie Ravi, Ananth McCurdy, Boyd Zhang, Liying Mamedov, Alexandre Deabreu, Andrea Loblaw, Andrew |
| description | Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL).
Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474.
152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate–severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p |
| doi_str_mv | 10.1016/j.radonc.2018.02.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2015408750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814018301269</els_id><sourcerecordid>2015408750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-ca423cb772c59f25413e5e6fb8fe9b2196e45390562f02241fb68ad8eeaed8b33</originalsourceid><addsrcrecordid>eNp9UUtLxDAQDqLo-vgHIjnqoWuSNm3qQVjEFwgrsp5DmkzZrN22JtmV-gv82UZXPQoDc5jvMfMNQseUjCmh-fli7JTpWj1mhIoxYbHKLTSioigTIkSxjUYRViSCZmQP7Xu_IIQwkha7aI-VnFOW0hH6mLYakjeAl2bAa3B-5THEPiRdmINLjBqwD-CgC0oHq3HVmQFHZ_s9V_2AbYt7FSy0weM3G-a4d50PKgDWKoo7fPo4mT3dT2dnF3iC-7nygFmUaE23tO9gcHBWNYdop1aNh6OffoCeb65nV3fJw_T2_mrykOg0ZyHRKmOproqCaV7WjGc0BQ55XYkayorRMoeMpyXhOasJYxmtq1woIwAUGFGl6QE63ejGLV9X4INcWq-haVQL3crLmCbPiCg4idBsA9XxIO-glr2zS-UGSYn8-oFcyM0PvlhCEharjLSTH4dVtQTzR_oNPQIuNwCId64tOOl1jE-DsQ50kKaz_zt8AmlYm3Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015408750</pqid></control><display><type>article</type><title>Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Quon, Harvey C. ; Ong, Aldrich ; Cheung, Patrick ; Chu, William ; Chung, Hans T. ; Vesprini, Danny ; Chowdhury, Amit ; Panjwani, Dilip ; Pang, Geordi ; Korol, Renee ; Davidson, Melanie ; Ravi, Ananth ; McCurdy, Boyd ; Zhang, Liying ; Mamedov, Alexandre ; Deabreu, Andrea ; Loblaw, Andrew</creator><creatorcontrib>Quon, Harvey C. ; Ong, Aldrich ; Cheung, Patrick ; Chu, William ; Chung, Hans T. ; Vesprini, Danny ; Chowdhury, Amit ; Panjwani, Dilip ; Pang, Geordi ; Korol, Renee ; Davidson, Melanie ; Ravi, Ananth ; McCurdy, Boyd ; Zhang, Liying ; Mamedov, Alexandre ; Deabreu, Andrea ; Loblaw, Andrew</creatorcontrib><description>Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL).
Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474.
152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate–severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p < 0.001). Acute urinary QOL was also better in the QW arm, with 52/67 (78%) vs 65/69 (94%) experiencing a MCIC (p = 0.006). There were no significant differences in late urinary or bowel QOL at 2 years or last follow-up.
Prostate SBRT delivered QW improved acute bowel and urinary QOL compared to EOD. Patients should be counselled regarding the potential for reduced short-term toxicity and improved QOL with QW prostate SBRT.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2018.02.029</identifier><identifier>PMID: 29551231</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Aged ; Dose Fractionation, Radiation ; Gastrointestinal Diseases - etiology ; Humans ; Male ; Patient Reported Outcome Measures ; Prostatic neoplasms ; Prostatic Neoplasms - radiotherapy ; Quality of Life ; Radiation Injuries - etiology ; Radiosurgery ; Radiosurgery - adverse effects ; Radiosurgery - methods ; Randomized controlled trial ; Stereotactic body radiotherapy ; Time Factors ; Toxicity ; Urination Disorders - etiology</subject><ispartof>Radiotherapy and oncology, 2018-05, Vol.127 (2), p.206-212</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-ca423cb772c59f25413e5e6fb8fe9b2196e45390562f02241fb68ad8eeaed8b33</citedby><cites>FETCH-LOGICAL-c362t-ca423cb772c59f25413e5e6fb8fe9b2196e45390562f02241fb68ad8eeaed8b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.radonc.2018.02.029$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29551231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quon, Harvey C.</creatorcontrib><creatorcontrib>Ong, Aldrich</creatorcontrib><creatorcontrib>Cheung, Patrick</creatorcontrib><creatorcontrib>Chu, William</creatorcontrib><creatorcontrib>Chung, Hans T.</creatorcontrib><creatorcontrib>Vesprini, Danny</creatorcontrib><creatorcontrib>Chowdhury, Amit</creatorcontrib><creatorcontrib>Panjwani, Dilip</creatorcontrib><creatorcontrib>Pang, Geordi</creatorcontrib><creatorcontrib>Korol, Renee</creatorcontrib><creatorcontrib>Davidson, Melanie</creatorcontrib><creatorcontrib>Ravi, Ananth</creatorcontrib><creatorcontrib>McCurdy, Boyd</creatorcontrib><creatorcontrib>Zhang, Liying</creatorcontrib><creatorcontrib>Mamedov, Alexandre</creatorcontrib><creatorcontrib>Deabreu, Andrea</creatorcontrib><creatorcontrib>Loblaw, Andrew</creatorcontrib><title>Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL).
Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474.
152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate–severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p < 0.001). Acute urinary QOL was also better in the QW arm, with 52/67 (78%) vs 65/69 (94%) experiencing a MCIC (p = 0.006). There were no significant differences in late urinary or bowel QOL at 2 years or last follow-up.
Prostate SBRT delivered QW improved acute bowel and urinary QOL compared to EOD. Patients should be counselled regarding the potential for reduced short-term toxicity and improved QOL with QW prostate SBRT.</description><subject>Aged</subject><subject>Dose Fractionation, Radiation</subject><subject>Gastrointestinal Diseases - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Patient Reported Outcome Measures</subject><subject>Prostatic neoplasms</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Quality of Life</subject><subject>Radiation Injuries - etiology</subject><subject>Radiosurgery</subject><subject>Radiosurgery - adverse effects</subject><subject>Radiosurgery - methods</subject><subject>Randomized controlled trial</subject><subject>Stereotactic body radiotherapy</subject><subject>Time Factors</subject><subject>Toxicity</subject><subject>Urination Disorders - etiology</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UUtLxDAQDqLo-vgHIjnqoWuSNm3qQVjEFwgrsp5DmkzZrN22JtmV-gv82UZXPQoDc5jvMfMNQseUjCmh-fli7JTpWj1mhIoxYbHKLTSioigTIkSxjUYRViSCZmQP7Xu_IIQwkha7aI-VnFOW0hH6mLYakjeAl2bAa3B-5THEPiRdmINLjBqwD-CgC0oHq3HVmQFHZ_s9V_2AbYt7FSy0weM3G-a4d50PKgDWKoo7fPo4mT3dT2dnF3iC-7nygFmUaE23tO9gcHBWNYdop1aNh6OffoCeb65nV3fJw_T2_mrykOg0ZyHRKmOproqCaV7WjGc0BQ55XYkayorRMoeMpyXhOasJYxmtq1woIwAUGFGl6QE63ejGLV9X4INcWq-haVQL3crLmCbPiCg4idBsA9XxIO-glr2zS-UGSYn8-oFcyM0PvlhCEharjLSTH4dVtQTzR_oNPQIuNwCId64tOOl1jE-DsQ50kKaz_zt8AmlYm3Y</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Quon, Harvey C.</creator><creator>Ong, Aldrich</creator><creator>Cheung, Patrick</creator><creator>Chu, William</creator><creator>Chung, Hans T.</creator><creator>Vesprini, Danny</creator><creator>Chowdhury, Amit</creator><creator>Panjwani, Dilip</creator><creator>Pang, Geordi</creator><creator>Korol, Renee</creator><creator>Davidson, Melanie</creator><creator>Ravi, Ananth</creator><creator>McCurdy, Boyd</creator><creator>Zhang, Liying</creator><creator>Mamedov, Alexandre</creator><creator>Deabreu, Andrea</creator><creator>Loblaw, Andrew</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201805</creationdate><title>Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial</title><author>Quon, Harvey C. ; Ong, Aldrich ; Cheung, Patrick ; Chu, William ; Chung, Hans T. ; Vesprini, Danny ; Chowdhury, Amit ; Panjwani, Dilip ; Pang, Geordi ; Korol, Renee ; Davidson, Melanie ; Ravi, Ananth ; McCurdy, Boyd ; Zhang, Liying ; Mamedov, Alexandre ; Deabreu, Andrea ; Loblaw, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-ca423cb772c59f25413e5e6fb8fe9b2196e45390562f02241fb68ad8eeaed8b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Dose Fractionation, Radiation</topic><topic>Gastrointestinal Diseases - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Patient Reported Outcome Measures</topic><topic>Prostatic neoplasms</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Quality of Life</topic><topic>Radiation Injuries - etiology</topic><topic>Radiosurgery</topic><topic>Radiosurgery - adverse effects</topic><topic>Radiosurgery - methods</topic><topic>Randomized controlled trial</topic><topic>Stereotactic body radiotherapy</topic><topic>Time Factors</topic><topic>Toxicity</topic><topic>Urination Disorders - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quon, Harvey C.</creatorcontrib><creatorcontrib>Ong, Aldrich</creatorcontrib><creatorcontrib>Cheung, Patrick</creatorcontrib><creatorcontrib>Chu, William</creatorcontrib><creatorcontrib>Chung, Hans T.</creatorcontrib><creatorcontrib>Vesprini, Danny</creatorcontrib><creatorcontrib>Chowdhury, Amit</creatorcontrib><creatorcontrib>Panjwani, Dilip</creatorcontrib><creatorcontrib>Pang, Geordi</creatorcontrib><creatorcontrib>Korol, Renee</creatorcontrib><creatorcontrib>Davidson, Melanie</creatorcontrib><creatorcontrib>Ravi, Ananth</creatorcontrib><creatorcontrib>McCurdy, Boyd</creatorcontrib><creatorcontrib>Zhang, Liying</creatorcontrib><creatorcontrib>Mamedov, Alexandre</creatorcontrib><creatorcontrib>Deabreu, Andrea</creatorcontrib><creatorcontrib>Loblaw, Andrew</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quon, Harvey C.</au><au>Ong, Aldrich</au><au>Cheung, Patrick</au><au>Chu, William</au><au>Chung, Hans T.</au><au>Vesprini, Danny</au><au>Chowdhury, Amit</au><au>Panjwani, Dilip</au><au>Pang, Geordi</au><au>Korol, Renee</au><au>Davidson, Melanie</au><au>Ravi, Ananth</au><au>McCurdy, Boyd</au><au>Zhang, Liying</au><au>Mamedov, Alexandre</au><au>Deabreu, Andrea</au><au>Loblaw, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2018-05</date><risdate>2018</risdate><volume>127</volume><issue>2</issue><spage>206</spage><epage>212</epage><pages>206-212</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL).
Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474.
152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate–severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p < 0.001). Acute urinary QOL was also better in the QW arm, with 52/67 (78%) vs 65/69 (94%) experiencing a MCIC (p = 0.006). There were no significant differences in late urinary or bowel QOL at 2 years or last follow-up.
Prostate SBRT delivered QW improved acute bowel and urinary QOL compared to EOD. Patients should be counselled regarding the potential for reduced short-term toxicity and improved QOL with QW prostate SBRT.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>29551231</pmid><doi>10.1016/j.radonc.2018.02.029</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-8140 |
| ispartof | Radiotherapy and oncology, 2018-05, Vol.127 (2), p.206-212 |
| issn | 0167-8140 1879-0887 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2015408750 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Dose Fractionation, Radiation Gastrointestinal Diseases - etiology Humans Male Patient Reported Outcome Measures Prostatic neoplasms Prostatic Neoplasms - radiotherapy Quality of Life Radiation Injuries - etiology Radiosurgery Radiosurgery - adverse effects Radiosurgery - methods Randomized controlled trial Stereotactic body radiotherapy Time Factors Toxicity Urination Disorders - etiology |
| title | Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A40%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Once-weekly%20versus%20every-other-day%20stereotactic%20body%20radiotherapy%20in%20patients%20with%20prostate%20cancer%20(PATRIOT):%20A%20phase%202%20randomized%20trial&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Quon,%20Harvey%20C.&rft.date=2018-05&rft.volume=127&rft.issue=2&rft.spage=206&rft.epage=212&rft.pages=206-212&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2018.02.029&rft_dat=%3Cproquest_cross%3E2015408750%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2015408750&rft_id=info:pmid/29551231&rft_els_id=S0167814018301269&rfr_iscdi=true |